{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:20:27Z","timestamp":1777785627285,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Am Psychiatr Nurses Assoc"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) is common and deadly. Naltrexone is a treatment for AUD. Previous research examined factors that predict Ohio Advanced Practice Registered Nurses\u2019 (APRNs) utilization of naltrexone to treat AUD. Inclusion criteria included APRNs\u2019 endorsing receipt of the X-waiver, a designation indicating providers\u2019 receipt of substance use disorder education. In 2023, the X-waiver was eliminated. The purpose of this study was to replicate the previous research design in respondents without an X-waiver and compare findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aims of this study were three-fold: (1) assess whether race, age, practice setting, years in practice, or work experience with an addiction specialist physician predicted prescription of naltrexone for AUD, (2) assess whether the goal of abstinence or reduced alcohol use as desired treatment affected the likelihood of naltrexone prescription for AUD, and (3) compare differences between the answers in the current respondent group without X-waiver and the previous study\u2019s X-waivered respondents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>All Ohio APRNs were sent surveys. Eighty-eight responses were included in analysis. Descriptive statistics, logistic regression, and chi-square results were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Work experience with an addiction specialist physician was negatively associated with prescribing naltrexone for AUD. Respondents from the previous study of X-waivered APRNs were significantly more likely to prescribe naltrexone for reduced alcohol consumption as a treatment outcome than the respondents in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The recent policy change eliminating the X-waiver provides important context for research, adding to the substance use disorder literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10783903241271273","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T02:33:11Z","timestamp":1724034791000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Ohio Advanced Practice Registered Nurses\u2019 Rate of Prescribing Naltrexone for Patients With Alcohol Use Disorder Since Elimination of the X-Waiver"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-0144","authenticated-orcid":false,"given":"Morgan","family":"Wiggins","sequence":"first","affiliation":[{"name":"Morgan Wiggins, DNP, APRN, PMHNP-BC, The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Smith","sequence":"additional","affiliation":[{"name":"Amy Smith, DNP, MSW, APRN, PMHNP-BC, FNP-BC, The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6883-9684","authenticated-orcid":false,"given":"Nathan","family":"Helsabeck","sequence":"additional","affiliation":[{"name":"Nathan Helsabeck, PhD, The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Achanta G. Kosten T. Fordis M. (2021 January). Clinician summary: Pharmacotherapy for adults with Alcohol Use Disorder (AUD) in outpatient settings. Agency for Healthcare Research and Quality. https:\/\/effectivehealthcare.ahrq.gov\/products\/alcohol-misuse-drug-therapy\/clinician"},{"key":"e_1_3_2_3_1","unstructured":"American Association of Nurse Practitioners. (2023 October). Ohio state policy fact sheet. https:\/\/www.aanp.org\/advocacy\/state\/state-practice-environment\/state-policy-fact-sheets\/ohio-state-policy-fact-sheet"},{"key":"e_1_3_2_4_1","unstructured":"American Nurses Association. (2017 October 19). Advanced Practice Registered Nurse. https:\/\/www.nursingworld.org\/practice-policy\/workforce\/what-is-nursing\/aprn\/"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Avery J. (2022). Naltrexone and alcohol use. The American Journal of Psychiatry 179(12) 886\u2013887. https:\/\/doi.org\/10.1176\/appi.ajp.20220821","DOI":"10.1176\/appi.ajp.20220821"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Beckman R. J. Cook R. D. (1983). Outlier\u2026\u2026\u2026.s. Technometrics 25(2) 119\u2013149. https:\/\/doi.org\/10.2307\/1268541","DOI":"10.1080\/00401706.1983.10487840"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Chockalingam L. Burnham E. L. Jolley S. E. (2022). Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system. Alcoholism: Clinical & Experimental Research 46 1094\u20131102. https:\/\/doi.org\/10.1111\/acer.14837","DOI":"10.1111\/acer.14837"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Cook R. D. Weisberg S. (1980). Characterizations of an empirical influence function for detecting influential cases in regression. Technometrics 22(4) 495\u2013508. https:\/\/doi.org\/10.2307\/1268187","DOI":"10.1080\/00401706.1980.10486199"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Ehrie J. Hartwell E. E. Morris P. E. Mark T. L. Kranzler H. R. (2020). Survey of addiction specialists\u2019 use of medications to treat alcohol use disorder. Frontiers in Psychiatry 11(47) 1\u20138. https:\/\/doi.org\/10.3389\/fpsyt.2020.00047","DOI":"10.3389\/fpsyt.2020.00047"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3758\/BF03193146"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000500521"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Jones K. F. Jacobs M. O. Spetz J. Hailer L. Tierney M. (2023). Eliminate the buprenorphine DEA x waiver: Justification using a policy analysis approach. Journal of Nursing Scholarship 55(3) 655\u2013664. https:\/\/doi.org\/10.1111\/jnu.12871","DOI":"10.1111\/jnu.12871"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Mann K. Batra A. Fauth-Buhler M. Hoch E. & The Guideline Group. (2017). German guidelines on screening diagnosis and treatment of alcohol use disorders. European Addiction Research 23 45\u201360. https:\/\/doi.org\/10.1159\/000455841","DOI":"10.1159\/000455841"},{"key":"e_1_3_2_14_1","unstructured":"National Center for Drug Abuse Statistics. (2023a). Alcohol abuse statistics. https:\/\/drugabusestatistics.org\/alcohol-abuse-statistics\/"},{"key":"e_1_3_2_15_1","unstructured":"National Center for Drug Abuse Statistics. (2023b). Drug overdose death rates. https:\/\/drugabusestatistics.org\/drug-overdose-deaths\/"},{"key":"e_1_3_2_16_1","unstructured":"National Center for Drug Abuse Statistics. (2023c). Opioid epidemic: Addiction statistics. https:\/\/drugabusestatistics.org\/opioid-epidemic\/"},{"key":"e_1_3_2_17_1","unstructured":"National Institute on Alcohol Abuse and Alcoholism. (n.d.). What is Alcohol Use Disorder (AUD)? https:\/\/alcoholtreatment.niaaa.nih.gov\/what-to-know\/alcohol-use-disorder"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Patel I. Li L. Jeong H. McDaniel J. T. McIntosh S. Roberston E. Albright D. L. (2023). Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama. Journal of Addictive Diseases. Advance online publication. https:\/\/doi.org\/10.1080\/10550887.2023.2247950","DOI":"10.1080\/10550887.2023.2247950"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Ranganathan P. Pramesh C. S. Aggarwal R. (2017). Common pitfalls in statistical analysis: Logistic regression. Perspectives in Clinical Research 8(3) 148\u2013151. https:\/\/doi.org\/10.4103\/picr.PICR_87_17","DOI":"10.4103\/picr.PICR_87_17"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.1750101"},{"key":"e_1_3_2_21_1","unstructured":"Rule 4723-8-04. Standard care arrangement for a certified nurse-midwife certified nurse practitioner and clinical nurse specialist Ohio Administrative Code (2\/1\/2022). https:\/\/codes.ohio.gov\/ohio-administrative-code\/rule-4723-8-04"},{"key":"e_1_3_2_22_1","volume-title":"National substance use and mental health services survey (N-SUMHSS) 2022: Data on substance use and mental health treatment facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2023","unstructured":"Substance Abuse and Mental Health Services Administration. (2023a). National substance use and mental health services survey (N-SUMHSS) 2022: Data on substance use and mental health treatment facilities. Center for Behavioral Health Statistics and Quality."},{"key":"e_1_3_2_23_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2023b October 10). Waiver elimination (MAT Act). https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0896-2757"},{"key":"e_1_3_2_25_1","first-page":"277","article-title":"First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario","volume":"63","author":"Spithoff S.","year":"2017","unstructured":"Spithoff S., Turner S., Gomes T., Martins D., Singh S. (2017). First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Canadian Family Physician, 63, 277\u2013283.","journal-title":"Canadian Family Physician"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Wiggins M. Painter S. Burant C. Juratovac E. Alto K. (2024). Understanding Ohio X-waivered advanced practice registered nurses\u2019 rate of naltrexone prescription for alcohol use disordered patients. Journal of the American Psychiatric Nurses Association 30(3) 613\u2013623. https:\/\/doi.org\/10.1177\/10783903221151062","DOI":"10.1177\/10783903221151062"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Wood E. Bright J. Hsu K. Goel N. Ross J. W. Hanson A. Teed R. Poulin G. Denning B. Corace K. Chase C. Halpape K. Lim R. Kealey T. Rehm J. (2023). Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. Canadian Medical Association Journal 195(40) E1364\u2013E1379. http:\/\/doi.org\/10.1503\/cmaj.230715","DOI":"10.1503\/cmaj.230715"},{"key":"e_1_3_2_28_1","unstructured":"World Health Organization. (2022 May 9). Alcohol: Key facts. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol"}],"container-title":["Journal of the American Psychiatric Nurses Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903241271273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10783903241271273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903241271273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:44:36Z","timestamp":1777491876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10783903241271273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10783903241271273"],"URL":"https:\/\/doi.org\/10.1177\/10783903241271273","relation":{},"ISSN":["1078-3903","1532-5725"],"issn-type":[{"value":"1078-3903","type":"print"},{"value":"1532-5725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,18]]}}}